New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Translating Innovation into Therapies
Antimicrobial Resistance and Drug Commercialization Were Key Topics at the Recent ON Helix Conference in Cambridge, U.K.
Literature Review: Dielectrophoresis to the Fore
Old Methodology Resurrected to Allow Inexpensive Label-Free Separation of Cell Populations
- Malmmosevej 19C
- Holte , DK-2840
CerCell is a ‘spin-off’ FP6 research-program and a 100% daughter company of Stobbe Tech A/S www.stobbe.com. CerCell is responsible for commercialization of the product portfolio for the pharmaceutical and chemical industry